Decreased half-life time of plasma von Willebrand factor collagen binding activity in essential thrombocythaemia: normalization after cytoreduction of the increased platelet count

被引:45
作者
van Genderen, PJJ
Prins, FJ
Lucas, IS
Van de Moesdijk, D
Van Vliet, HHDM
Van Strik, R
Michiels, JJ
机构
[1] Univ Hosp Dijkzigt, Dept Haematol, NL-3015 GD Rotterdam, Netherlands
[2] Erasmus Univ, Inst Epidemiol & Biostat, Rotterdam, Netherlands
关键词
von Willebrand factor; platelets; collagen; kinetics; essential thrombocythaemia;
D O I
10.1046/j.1365-2141.1997.4823285.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Patients with essential thrombocythaemia (ET) exhibit a decrease of large von Willebrand fatter (VWF) multimers in plasma, which is inversely related to the platelet count. In the present study we investigated whether the decrease of large VWF multimers in plasma with increasing platelet counts is the consequence of increased turnover of large VWF multimers in vivo. To that end we measured the half-life times of endogenously released VWF:Ag and VWF:CBA (collagen binding activity) after intravenous administration of desmopressin (DDAVP) to nine ET patients and nine control subjects (N). In addition, the half-life times of VWF:Ag and VWF:CBA were also measured in four ET patients after cytoreduction of the increased platelet count to normal or nearly normal values. Estimated half-life times of VWF:Ag did not differ between ET patients and normals (11.0 +/- 4.0h v 12.4 +/- 2.5h, P>0.05). Estimated half-life times of VWF:CBA were significantly lower in ET patients as compared with normal individuals (6.1 +/- 2.0h v 8.4 +/- 1.5 h, P <0.05). After cytoreduction of the increased platelet count to (nearly) normal values in all four ET patients the half-life time of VWF:CBA significantly (P = 0.014) increased from 5.2 +/- 1.2, h to 8.7 +/- 2.0 h. Our data suggest that platelets may play a role in the homeostasis of circulating von Willebrand factor, which may compromise normal haemostasis at fairly increased platelet counts.
引用
收藏
页码:832 / 836
页数:5
相关论文
共 26 条
[1]  
BELLUCCI S, 1986, CANCER, V58, P2440, DOI 10.1002/1097-0142(19861201)58:11<2440::AID-CNCR2820581115>3.0.CO
[2]  
2-Y
[3]  
BERKOWITZ SD, 1988, BLOOD, V72, P721
[4]  
BRODY T, 1994, HUMAN PHARM, P33
[5]  
BUDDE U, 1993, BLOOD, V82, P1749
[6]  
BUDDE U, 1986, BLOOD, V68, P1213
[7]  
BUDDE U, 1984, BLOOD, V64, P981
[8]   IDENTIFICATION OF A CLEAVAGE SITE DIRECTING THE IMMUNOCHEMICAL DETECTION OF MOLECULAR ABNORMALITIES IN TYPE-IIA VONWILLEBRAND-FACTOR [J].
DENT, JA ;
BERKOWITZ, SD ;
WARE, J ;
KASPER, CK ;
RUGGERI, ZM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1990, 87 (16) :6306-6310
[9]   VON WILLEBRANDS DISEASE - USE OF COLLAGEN-BINDING ASSAY PROVIDES POTENTIAL IMPROVEMENT TO LABORATORY MONITORING OF DESMOPRESSIN (DDAVP) THERAPY [J].
FAVALORO, EJ ;
DEAN, M ;
GRISPO, L ;
EXNER, T ;
KOUTTS, J .
AMERICAN JOURNAL OF HEMATOLOGY, 1994, 45 (03) :205-211
[10]  
FAVALORO EJ, 1995, AM J CLIN PATHOL, V104, P264